RO7836748

Primary Objectives: 1. To evaluate the safety and tolerability of RO7836748 as monotherapy and in combination with other antitumor therapies in patients with advanced solid tumors harboring the KRASG12V gene mutation. 2. To determine the maximum tolerated dose (MTD), maximum administered dose (MAD), and/or recommended dose (RDE) for the expansion phase of RO7836748 as monotherapy and in combination with other antitumor therapies, as well as the dosing regimen for the expansion phase. Secondary Objectives: 1. To describe the plasma pharmacokinetic (PK) characteristics of RO7836748 and its metabolites (if applicable) as monotherapy. 2. To describe the plasma PK characteristics of RO7836748 and its metabolites (if applicable) when administered in combination with other antitumor therapies. 3. To evaluate the preliminary clinical activity of RO7836748 as monotherapy and in combination with other antitumor therapies. Exploratory Objectives: 1. If assessing food effects, investigate the impact of food on the pharmacokinetics (PK) of RO7836748 after administration on an empty stomach or with food. 2. If assessing drug-drug interaction (DDI) effects, investigate the impact of drug-drug interactions (DDI) on the PK of RO7836748 when administered in combination with a proton pump inhibitor (PPI). 3. Identify and/or evaluate biomarkers associated with pharmacodynamics (PD), clinical activity, susceptibility to adverse events, response, and intrinsic and/or acquired resistance to RO7836748 monotherapy or in combination with other antitumor therapies.